top of page
Atticus in the News
Atticus Pharma licensed from Zylö Therapeutics the Z-pod® sustained-release technology that originated at Albert Einstein College of Medicine and that was further developed at Zylö. This platform technology forms the nucleus of Atticus's drug-development programs (see "Pipeline"). Some of the news items listed below were issued by Zylö prior to the license being forged, but relate to Atticus and its various programs.
Atticus accepted into NYU's Endless Frontier Labs [EFL] Mentorship Program
Only 78 of over 1,400 applicants accepted into this prestigious program that is designed to optimize each startup’s chance of scaling into a successful company.
bottom of page